Naringin as a benef i cial natural product against degeneration of the nigrostriatal dopaminergic projection in the adult brain

Naringin as a benef i cial natural product against degeneration of the nigrostriatal dopaminergic projection in the adult brain

Microglia are the resident immune cells of the central nervous system (CNS) and the major cause of CNS neurotoxic inf l ammation in response to a variety of stimuli, including infection, trauma, and toxins (Kim et al., 2010; Shin et al., 2015). Microglia are stimulated by various activators, and undergo phagocytic morphological changes, which are characterized by an enlarged cell body and short processes (Kim et al., 2010; Shin et al., 2015).ey then produce neurotoxic inf l ammatory cytokines such as IL-1β, TNF-α, and IL-6 (Kim et al., 2010; Jung et al., 2014; Nam et al., 2014; Jeong et al., 2015; Shin et al., 2015; Leem et al., 2016; Jang et al., 2017). In addition, activated microglia can produce reactive oxygen species (ROS) such as O2−and O2−-derived oxidants, and excessive ROS production is implicated in the death of DA neurons in the adult brain (Choi et al., 2005; Kim et al., 2010; Chung et al., 2011).

mTOR kinase, which plays central roles in the integration of cell growth in response to various environmental conditions, exists in two complexes, mTOR complex 1 (mTORC1) and mTORC2 (Kim et al., 2012; Kim, 2014; Jeon et al., 2015). mTORC1 is an important mediator of protein kinase B (Akt). mTORC2 can activate Akt, which in turn can act on mTORC1. Activation of the Akt/mTOR signaling pathway enhances the activity of intracellular cell survival pathways, under a variety of conditions, including trophic factor withdrawal, ischemic shock, and oxidative stress (Cheng et al., 2011; Kim et al., 2011, 2012; Nam et al., 2015; Jeon et al., 2015). Moreover, recent reports showed that the activation of neuronal mTORC1 (a key biomolecule for neurotrophic support) by either the delivery of a specif i c gene or the direct administration of trophic factors, could induce protective effects against neurodegeneration in animal models of PD (Siegel and Chauhan, 2000; Allen et al., 2013; Nam et al., 2015).

As described above, a large body of experimental evidence suggests that the control of microglial activation and the induction of mTORC1 in DA neurons may be important to prevent the degeneration of DA neurons in PD. However, there is no report of a successful clinical trial with chemical compounds inhibiting microglial activation for anti-neurodegeneration in PD, and the treatment with neurotrophic factors to activate mTORC1 has a critical problem because they do not cross the blood-brain barrier, which is the membrane protecting the brain from exogenous pathogen/toxic agents through the structural and functional complex, thus direct application of neurotrophic factors to the brain is needed (Kim et al., 2012; Kim, 2014; Nam et al., 2015).us, we need to develop other therapeutics, which are capable to control microglial activation and induce activation of mTORC1 in DA neurons, easily reaching to the brain for PD treatment.

Using natural compounds such as phytochemicals to inhibit microglial activation and induce mTORC1 activation in adult neurons may be useful for the development of a novel protective agent for the nigrostriatal DA system in the adult brain. Moreover, phytochemicals are usually considered to be harmless to health.ey are also less toxic and have fewer side ef f ects than synthetic drugs. Among many kinds of phytochemicals, naringin is a well-known fl avanone glycoside found in grapefruits and citrus fruits (Singh et al., 2003; Choi et al., 2010; Golechha et al., 2011; Rong et al., 2012; Xianchu et al., 2016). It has the ability to exert a variety of biological and pharmacological effects, including anti-inf l ammatory, anti-oxidant, and lipid-lowering activities (Kim et al., 2009; Choi et al., 2010; Golechha et al., 2011; Rong et al., 2012; Leem et al., 2014; Xianchu et al., 2016). Naringin has recently been considered as a potential protective agent against neurodegenerative diseases, due to its anti-oxidant and neuroprotective activities (Choi et al., 2010; Golechha et al., 2011; Leem et al., 2014; Kim et al., 2016).e anti-oxidant effects by naringin administration modulate the oxidative stress and inf l ammatory responses in the adult brain, and its neuroprotective ef f ects are also controlled by the induction of neurotrophic factors and the activation of anti-apoptotic pathways (Rong et al., 2012; Leem et al., 2014; Kim et al., 2016). However, it was largely unknown whether naringin can have neuroprotective ef f ects against degeneration of the nigrostriatal DA projection in the adult brain, which is associated with PD.

Our recent observations of the effects of naringin in animal models of PD showed that its treatment could protect the whole nigrostriatal DA projection from neurotoxicity in the adult brain (Leem et al., 2014; Kim et al., 2016). Treatment with naringin could activate mTORC1 in adult DA neuronsin vivo(Leem et al., 2014; Kim et al., 2016), and its administration gave DA neurons the ability to produce glial cell line-derived neurotrophic factor (GDNF) which acts against degeneration of DA neurons (Leem et al., 2014; Kim et al., 2016), suggesting that it might be a beneficial natural compound for the activation of neurotrophic signaling pathways. It also attenuated microglial activation in a neurotoxin-treated animal model of PD, which consequentially produced anti-inflammatory effects such as a reduction in neurotoxic cytokines (Leem et al., 2014; Kim et al., 2016). Although treatment with naringin was not suf fi cient to restore the lesioned nigrostriatal DA projection in a mouse model of PD (Kim et al., 2016), these observations suggest that naringin maybe possess the ability to further prevent against neurodegeneration in PD (Leem et al., 2014; Kim et al., 2016). Currently, there is a lack of evidence of any neuroprotective role of naringin in clinical trials, and our knowledge of themechanisms of naringin-mediated effects in the nigrostriatal DA system is insuf fi cient.erefore, further studies are needed to evaluate naringin-induced ef f ects on the adult brain in detail and to investigate whether naringin can prevent against neurodegeneration in humans. In addition, it may be worthwhile to test consistently whether other phytochemicals, which are known to have similar physiological activities to naringin (Jung et al., 2014; Jeong et al., 2015), can modulate microglial activation and insufficient neurotrophic supports in the adult brain because appropriate usage of these natural compounds may be a useful strategy to protect and maintain the nigrostriatal DA system in the adult brain.

This study was supported by grants from the Korea Healthcare Technology R&D Project, Ministry of Health & Welfare (HI15C1928) and the National Research Foundation of Korea (NRF-2017R1A2B4002675).

Sang Ryong Kim

School of Life Sciences; BK21 plus KNU Creative BioResearch Group; Brain Science and Engineering Institute, Kyungpook National University, Daegu, Korea

*Correspondence to: Sang Ryong Kim, Ph.D., srk75@knu.ac.kr.

orcid: 0000-0003-0299-1613 (Sang Ryong Kim)

Accepted:2017-08-01

How to cite this article:Kim SR (2017) Naringin as a benef i cial natural product against degeneration of the nigrostriatal dopaminergic projection in the adult brain. Neural Regen Res 12(8):1375-1376.

Plagiarism check: Checked twice by ienticate.

Peer review: Externally peer reviewed.

Open access statement:is is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Open peer reviewer: Daniel M. Johnstone, University of Sydney, Australia.

Allen SJ, Watson JJ, Shoemark DK, Barua NU and Patel NK (2013) GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacoler 138:155-175.

Cheng HC, Kim SR, Oo TF, Kareva T, Yarygina O, Rzhetskaya M, Wang C, During M, Talloczy Z, Tanaka K, Komatsu M, Kobayashi K, Okano H, Kholodilov N, Burke RE (2011) Akt suppresses retrograde degeneration of dopaminergic axons by inhibition of macroautophagy. J Neurosci 31:2125-2135.

Choi BS, Sapkota K, Kim S, Lee HJ, Choi HS, Kim SJ (2010) Antioxidant activity and protective ef f ects of Tripterygium regelii extract on hydrogen peroxide-induced injury in human dopaminergic cells, SH-SY5Y. Neurochem Res 35:1269-1280.

Choi SH, Lee DY, Chung ES, Hong YB, Kim SU, Jin BK (2005) Inhibition of thrombin-induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo. J Neurochem 95:1755-1765.

Chung YC, Kim SR, Park JY, Chung ES, Park KW, Won SY, Bok E, Jin M, Park ES, Yoon SH, Ko HW, Kim YS, Jin BK (2011) Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology 60:963-974.

Golechha M, Chaudhry U, Bhatia J, Saluja D, Arya DS (2011) Naringin protects against kainic acid-induced status epilepticus in rats: evidence for an antioxidant, anti-inf l ammatory and neuroprotective intervention. Biol Pharm Bull 34:360-365.

Jang H, Kim S, Lee JM, Oh YS, Park SM, Kim SR (2017) Montelukast treatment protects nigral dopaminergic neurons against microglial activation in the 6-hydroxydopamine mouse model of Parkinson’s disease. Neuroreport 28:242-249.

Jeon MT, Nam JH, Shin WH, Leem E, Jeong KH, Jung UJ, Bae YS, Jin YH, Kholodilov N, Burke RE, Lee SG, Jin BK, Kim SR (2015) In vivo AAV1 transduction with hRheb(S16H) protects hippocampal neurons by BDNF production. Moler 23:445-455.

Jeong KH, Jeon MT, Kim HD, Jung UJ, Jang MC, Chu JW, Yang SJ, Choi IY, Choi MS, Kim SR (2015) Nobiletin protects dopaminergic neurons in the 1-methyl-4-phenylpyridinium-treated rat model of Parkinson’s disease.J Med Food 18:409-414.

Jung UJ, Jeon MT, Choi MS, Kim SR (2014) Silibinin attenuates MPP+-induced neurotoxicity in the substantia nigra in vivo. J Med Food 17:599-605.

Kim HD, Jeong KH, Jung UJ, Kim SR (2016) Naringin treatment induces neuroprotective ef f ects in a mouse model of Parkinson’s disease in vivo, but not enough to restore the lesioned dopaminergic system. J Nutr Biochem 28:140-146.

Kim HJ, Song JY, Park HJ, Park HK, Yun DH, Chung JH (2009) Naringin Protects against Rotenone-induced Apoptosis in Human Neuroblastoma SH-SY5Y Cells. Korean J Physiol Pharmacol 13:281-285.

Kim SR (2014) Mammalian target of rapamycin complex 1 as an inducer of neurotrophic factors in dopaminergic neurons. Neural Regen Res 9:2036-2037.

Kim SR, Chen X, Oo TF, Kareva T, Yarygina O, Wang C, During M, Kholodilov N, Burke RE (2011) Dopaminergic pathway reconstruction by Akt/ Rheb-induced axon regeneration. Ann Neurol 70:110-120.

Kim SR, Chung ES, Bok E, Baik HH, Chung YC, Won SY, Joe E, Kim TH, Kim SS, Jin MY, Choi SH, Jin BK (2010) Prothrombin kringle-2 induces death of mesencephalic dopaminergic neurons in vivo and in vitro via microglial activation. J Neurosci Res 88:1537-1548.

Kim SR, Kareva T, Yarygina O, Kholodilov N, Burke RE (2012) AAV transduction of dopamine neurons with constitutively active Rheb protects from neurodegeneration and mediates axon regrowth.Mol Ther 20:275-286.

Leem E, Jeong KH, Won SY, Shin WH, Kim SR (2016) prothrombin kringle-2: a potential inf l ammatory pathogen in the parkinsonian dopaminergic system. Exp Neurobiol 25:147-155.

Leem E, Nam JH, Jeon MT, Shin WH, Won SY, Park SJ, Choi MS, Jin BK, Jung UJ, Kim SR (2014) Naringin protects the nigrostriatal dopaminergic projection through induction of GDNF in a neurotoxin model of Parkinson’s disease. J Nutr Biochem 25:801-806.

Nam JH, Leem E, Jeon MT, Kim YJ, Jung UJ, Choi MS, Maeng S, Jin BK, Kim SR (2014) Inhibition of prothrombin kringle-2-induced inf l ammation by minocycline protects dopaminergic neurons in the substantia nigra in vivo. Neuroreport 25:489-495.

Nam JH, Leem E, Jeon MT, Jeong KH, Park JW, Jung UJ, Kholodilov N, Burke RE, Jin BK, Kim SR (2015) Induction of GDNF and BDNF by hRheb(S16H) transduction of SNpc neurons: neuroprotective mechanisms of hRheb(S16H) in a model of Parkinson’s disease. Mol Neurobiol 51:487-499.

Rong W, Wang J, Liu X, Jiang L, Wei F, Hu X, Han X, Liu Z (2012) Naringin treatment improves functional recovery by increasing BDNF and VEGF expression, inhibiting neuronal apoptosis aer spinal cord injury. Neurochem Res 37:1615-1623.

Shin WH, Jeon MT, Leem E, Won SY, Jeong KH, Park SJ, McLean C, Lee SJ, Jin BK, Jung UJ, Kim SR (2015) Induction of microglial toll-like receptor 4 by prothrombin kringle-2: a potential pathogenic mechanism in Parkinson’s disease. Sci Rep 5:14764.

Siegel GJ and Chauhan NB (2000) Neurotrophic factors in Alzheimer’s and Parkinson’s disease brain. Brain Res Brain Res Rev 33: 199-227.

Singh D, Chander V, Chopra K (2003) Protective ef f ect of naringin, a biof l avonoid on ferric nitrilotriacetate-induced oxidative renal damage in rat kidney. Toxicology 201:1-8.

Xianchu L, Lan PZ, Qiufang L, Yi L, Xiangcheng R, Wenqi H, Yang D (2016) Naringin protects against lipopolysaccharide-induced cardiac injury in mice. Environ Toxicol Pharmacol 48:1-6.

Copyedited by Li CH, Song LP, Zhao M

10.4103/1673-5374.213694